Oncology

ASCO guidelines reshape multiple myeloma care with quadruplet induction, earlier CAR T-cell therapy and bispecifics, and selective smoldering treatment.

Amy Seung outlines her priorities for leading HOPA through evolving therapies, workforce challenges, and expanding pharmacy roles.

Phase 3 trial data show that isatuximab quadruplet improves MRD negativity in transplant-eligible patients with multiple myeloma.

Pacritinib bridges high-risk myelofibrosis to allogeneic stem cell transplantation, preserving blood counts, shrinking spleen and symptoms, and enabling 95% of patients to undergo transplantation.

Air pollution exposure, particularly fine particulate matter and ozone, may worsen cardiac outcomes in patients with breast cancer receiving cardiotoxic therapies.

Waters Corporation's Onclarity HPV Self-Collection Kit represents a significant advance in expanding access to cervical cancer screening outside the clinic.

Phase 3 PATCH trial data show estrogen patches reduce hot flashes but raise gynecomastia risk.

Myelofibrosis model reveals malignant stem cells reprogram healthy support cells, fueling inflammation and fibrosis.

Octogenarians with early-stage non–small cell lung cancer (NSCLC) can safely undergo surgery and achieve survival and quality-of-life outcomes comparable to those of younger patients.

Team-based, multidisciplinary care aids personalized treatment, improving coordination across complex therapies, and enhances patient outcomes and long-term quality of life.

Circulating tumor DNA detected after neoadjuvant therapy may serve as a powerful biomarker for minimal residual disease and help predict breast cancer recurrence.

Selinexor plus ruxolitinib significantly improved spleen volume reduction in JAK inhibitor–naive myelofibrosis, supporting its potential as a novel frontline combination strategy.

New research identifies caspase-8 loss as a key driver of inflammatory reprogramming and tumor recurrence in small cell lung cancer.

Kelly Gable, PharmD, shares how empathy, presence, and practical guidance can transform patient experiences beyond the medication plan.

Alex Wolff, PharmD, BCOP, FHOPA, explains how patient populations, delivery models, and safety risks shape real-world implementation.

Gene and cell therapies are reshaping clinical workflows—and pharmacists are becoming essential guides in that shift.

Pharmacists and clinicians share strategies to streamline training, collaboration, and patient care with BTCEs.

Disease burden, monitoring strategy, and timing of therapy drive CRS risk and management.

Ivermectin, fenbendazole, and mebendazole have gained traction as alternative cancer therapies despite a lack of clinical evidence.

Experts discuss immunotherapy overlap, nutrition challenges, and clinical judgment with GLP-1 RA use.

Formal preceptor leadership pathways can reduce RPD burden and improve resident support across programs.

Oncology pharmacists face profound ethical tensions, often without formal training to navigate them.

Survivor and pharmacist Kelly Gable, PharmD, BCPP, FAAPP, explains the overlooked challenges shaping patients’ day-to-day lives.

Experts detail the workflows and decisions behind launching complex bispecific therapies.

Multicenter data suggests dexamethasone may safely replace tocilizumab for low-grade CRS.

Pharmacists at the 2026 HOPA Annual Meeting discuss medical misinformation and how to combat it.